For Diabetic Foot Ulcer, Heberprot-P is a drug developed by the Center for Genetic Engineering and Biotechnology (CIGB) in 2007 in Cuba. Diabetes is no longer considered life threatening, nonetheless diabetes and complications due to diabetes, when not under control, remain to be sixth leading cause of death having a higher mortality rate than some...
AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
Psoriasis is an incurable but treatable skin condition. One of the most effective treatments is Coriodemina, a water soluble gel developed in Cuba by Dr. Carlos Miyares Cao, world-renowned researcher holding a doctorate in Medicine from the University of Havana, Cuba, with a specialty in Gynecology, Obstetrics and Pharmacology and is Senior Research with approximately...
Vitiligo is generally thought of as an incurable disease and at most, people who suffer from this skin condition can only be treated in the hope of improving the appearance of the affected area. Melagenina Plus is an ointment developed in Cuba, has been shown to be effective in about 86% of the time....
Racotumomab (trade name Vaxira) is a non-small cell lung cancer (NSCLC) vaccine developed by researchers at the Center of Molecular Immunology, Cuba in collaboration with researchers from the Buenos Aires University, Argentina with promising results. It was granted certificate of approval by the State Center for Quality Control of Medicines of Cuba and by January,...
Patients in 34 Countries Recover Eyesight Thanks to Cuba and Venezuela All over Cuba these days there are celebrations of the tenth anniversary of “Operation Miracle.” The U.S. public knows almost nothing about this internationalized project involving the restoration of vision for enormous numbers of people. Set in motion on July 8, 2004, Operation Miracle...
Cimavax-EGF for Non-small Cell Lung Cancer Vaccine Cimavax-EGF is the first worldwide registered therapeutic vaccine for non-small lung cancer developed in Cuba by the Center for Molecular Immunology in conjunction with the Center for Genetic Engineering and Biotechnology. In 2008 it was approved by the Cuban regulatory authority for the use in adults with advanced...
where the DOCTOR IN DENTISTRY The Doctor in Dentistry has a mandatory pre-medical Spanish speaking students unless showing the mastery of the Spanish Language, demonstrated through a proficiency test (oral and written) at a price of 75 CUC which is not included in the price of any of the under grade careers
The Nursing has a mandatory pre-medical Spanish proficiency course for non spanish speaking students unless showing the mastery of the Spanish language, demonstrated through a pro-efficiency test (oral and written) at a price of 75.00 CUC which is included in the price of any of the Under Grade careers Introduction: Cuba is renowned for its...
Interviews From Havana
January 27, 2018by CubaHeal Research
Cuba is well known for its world class health-care, but also for its scientific research in the field, in places such as the Molecular Immunology Center, which develops new products to diagnose and treat cancer. Such institutes are also now profitible ventures for the island nation.
The recommended dose of CIMAher® is 200 mg given once a week for 6 weeks concomitant with radiotherapy and / or radio-chemotherapy. Subsequently, dose of 200 mg every 15 days (maintenance dose) until the general condition of the patient allows it.